![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1402532
Áß³²¹ÌÀÇ Æó¾Ï ½ºÅ©¸®´× ½ÃÀå ¿¹Ãø(-2030³â) : Áö¿ªº° ºÐ¼® - ¾Ï À¯Çü, ±â¼ú, ¿¬·ÉÃþ, ÃÖÁ¾»ç¿ëÀÚº°South & Central America Lung Cancer Screening Market Forecast to 2030 - Regional Analysis- by Cancer Type, Technology, Age Group (50 & Older and Below 50), and End User (Hospitals, Diagnostic Centers, and Others) |
Áß³²¹ÌÀÇ Æó¾Ï ½ºÅ©¸®´× ½ÃÀåÀº 2022³â 3,916¸¸ ´Þ·¯¿¡¼ 2030³â¿¡´Â 6,895¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2022-2030³âÀÇ CAGRÀº 7.3%·Î ÃßÁ¤µË´Ï´Ù.
Æó¾Ï ½ºÅ©¸®´× °Ë»çÀÇ °íºñ¿ëÀÌ Áß³²¹ÌÀÇ Æó¾Ï ½ºÅ©¸®´× ½ÃÀåÀ» ÃËÁø
ÀÌ Áö¿ª¿¡¼ ÀÇ·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÌ Áö¿ªÀÇ Æó¾Ï °ËÁø ÇÁ·Î¹ÙÀÌ´õ¿¡°Ô´Â ÃæºÐÇÑ ±âȸ°¡ ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â Áö¿ª º´¿ø ¹× Ŭ¸®´Ð°ú Çù·ÂÇÏ¿© Á¢±Ù¼ºÀÌ ÁÁÀº Æó¾Ï °ËÁøÀ» Á¦°øÇϰųª ¿ø°Ý ¿ø°ÝÀǷḦ Ȱ¿ëÇÏ´Â °ÍÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº Æó¾ÏÀ» Á¶±â¿¡ ¹ß°ßÇÒ »Ó¸¸ ¾Æ´Ï¶ó ȯÀÚÀÇ °á°ú¸¦ °³¼±Çϰí ÀÌ Áö¿ª ÀÇ·áÀÇ Áß¿äÇÑ °ÝÂ÷¸¦ ÇØ¼ÒÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ¹ß¸ÂÃß¾î ÀÌµé °ø±ÞÀÚ´Â À¯¸ÁÇÑ ½ÃÀå¿¡ ¹ßÆÇÀ» ¸¶·ÃÇÏ°í ±Ã±ØÀûÀ¸·Î Áö¿ª ÀüüÀÇ °øÁß º¸°Ç°ú º¹Áö Çâ»ó¿¡ ±â¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù.
Áß³²¹Ì Æó¾Ï °ËÁø ½ÃÀå °³¿ä
Áß³²¹Ì Æó¾Ï °ËÁø ½ÃÀåÀº ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª, ±âŸ Áß³²¹Ì·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áö¿ªÀÇ ¼ºÀåÀº Æó¾Ï ¹ßº´·ü Áõ°¡¿Í Æó¾Ï °ËÁø¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µî ´Ù¾çÇÑ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ °ËÁø¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø Áõ°¡´Â ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
Æó¾Ï °ËÁø ½ÃÀåÀº ¾Ï À¯º´·ü Áõ°¡¿Í °°Àº ¿äÀο¡ ÀÇÇØ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î Globocan 2020 º¸°í¼¿¡ µû¸£¸é Æó¾ÏÀº ºê¶óÁú¿¡¼ µÎ ¹øÂ°·Î ¹ßº´·üÀÌ ³ôÀº ¾ÏÀÔ´Ï´Ù. ºê¶óÁú¿¡¼ »õ·Î ¹ß°ßµÈ Æó¾Ï »ç·Ê´Â 88492°ÇÀ̾ú½À´Ï´Ù.
Æó¾Ï °ËÁøÀº Àü ¼¼°è¿¡¼ Ç¥ÁØ Ä¡·á·Î °£Áֵ˴ϴÙ. ºê¶óÁú¿¡¼´Â ÀÇ·á ½Ã½ºÅÛ Á¶Á÷, CT ½ºÄµ ¹× Ä¡·á¹ý¿¡ ´ëÇÑ Á¢±Ù¼º, ¹®ÈÀû ¼ö¿ë¼º µî°ú °ü·ÃµÈ º¹ÀâÇÑ ¹®Á¦µéÀÌ °ËÁø ½ÃÇà °úÁ¤À» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. ÇöÁö Á¶Á÷¿¡ µû¶ó °ËÁøÀ» ½ÃÇàÇÏ´Â µ¥¿¡´Â ¿©·¯ °¡Áö ¾î·Á¿ò°ú À庮ÀÌ ÀÖÁö¸¸, ¸ðµç ½Ã³ª¸®¿À¿¡¼ ¸¸Á·½º·¯¿î °á°ú¸¦ ¾òÀ» ¼ö ÀÖ¾ú½À´Ï´Ù.
Lung Cancer Policy Network¿¡ µû¸£¸é ºê¶óÁú¿¡¼´Â Æó¾Ï °ËÁø¿¡ ´ëÇÑ Çù·ÂÀû Á¢±ÙÀÌ ÇÊ¿äÇϸç, ÃÖ±Ù Á¦2ȸ ºê¶óÁú Á¶±â Æó¾Ï °ËÁø ½ÃÇè(BRELT2)¿¡¼ LDCT °ËÁøÀÇ ÀÌÁ¡ÀÌ º¸°íµÇ¾ú½À´Ï´Ù. ÇÏÁö¸¸ Àü±¹ÀûÀ¸·Î ü°èÀûÀÎ °ËÁø ÇÁ·Î±×·¥À» ½ÃÇàÇϱâ À§Çؼ´Â °ø°ø ÀÇ·á¿Í ¹Î°£ ÀÇ·á °£ °ËÁø Àåºñ¿¡ ´ëÇÑ ºÒÆòµîÇÑ Á¢±Ù¼º µî ±Øº¹ÇØ¾ß ÇÒ À庮ÀÌ ¿©ÀüÈ÷ ¸¹½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ Propulmao Mobile ProjectÀÇ ÀÏȯÀ¸·Î, »óÆÄ¿ï·çÀÇ ¹ß·¹Å佺½Ã º¸°Ç±¹Àº Áö¿ª ¾Ï º´¿ø°ú Çù·ÂÇÏ¿© Áö¿ª³» À̵¿½Ä LDCT °ËÁø ¹× ±Ý¿¬ ÁßÀ縦 ½Ç½ÃÇß½À´Ï´Ù.
Áß³²¹ÌÀÇ Æó¾Ï ½ºÅ©¸®´× ½ÃÀå ¸ÅÃâ°ú 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)
Áß³²¹ÌÀÇ Æó¾Ï ½ºÅ©¸®´× ½ÃÀå ¼¼ºÐÈ
Áß³²¹ÌÀÇ Æó¾Ï ½ºÅ©¸®´× ½ÃÀåÀº ¾Ï À¯Çü, ±â¼ú, ¿¬·ÉÃþ, ÃÖÁ¾»ç¿ëÀÚ, ±¹°¡º°·Î ±¸ºÐµË´Ï´Ù.
¾Ï À¯Çü¿¡ ±â¹ÝÇÏ¿© Áß³²¹ÌÀÇ Æó¾Ï ½ºÅ©¸®´× ½ÃÀåÀº ºñ¼Ò¼¼Æ÷Æó¾Ï(NSCLC)°ú ¼Ò¼¼Æ÷Æó¾ÏÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â Áß³²¹ÌÀÇ Æó¾Ï ½ºÅ©¸®´× ½ÃÀå¿¡¼´Â ºñ¼Ò¼¼Æ÷Æó¾Ï(NSCLC) ºÎ¹®ÀÌ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
±â¼ú¿¡ ±â¹ÝÇÏ¿© Áß³²¹ÌÀÇ Æó¾Ï ½ºÅ©¸®´× ½ÃÀåÀº ÈäºÎ X¼±, Àú¼±·® ÄÄÇ»ÅÍ´ÜÃþÃÔ¿µ(LDCT), ¾×ü»ý°Ë, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2022³â Áß³²¹ÌÀÇ Æó¾Ï ½ºÅ©¸®´× ½ÃÀå¿¡¼´Â ÈäºÎ X¼± ºÎ¹®ÀÌ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
¿¬·ÉÃþ¿¡ ±â¹ÝÇÏ¿© Áß³²¹ÌÀÇ Æó¾Ï ½ºÅ©¸®´× ½ÃÀåÀº 50¼¼ ÀÌ»ó°ú 50¼¼ ¹Ì¸¸À¸·Î ±¸ºÐµË´Ï´Ù. 50¼¼ ÀÌ»ó ºÎ¹®Àº 2022³â¿¡ Áß³²¹ÌÀÇ Æó¾Ï ½ºÅ©¸®´× ½ÃÀå¿¡¼ º¸´Ù Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
ÃÖÁ¾»ç¿ëÀÚ¿¡ ±â¹ÝÇÏ¿© Áß³²¹ÌÀÇ Æó¾Ï ½ºÅ©¸®´× ½ÃÀåÀº º´¿ø, Áø´Ü ¼¾ÅÍ, ±âŸ·Î ±¸ºÐµË´Ï´Ù. º´¿ø ºÎ¹®ÀÌ 2022³â Áß³²¹ÌÀÇ Æó¾Ï ½ºÅ©¸®´× ½ÃÀå¿¡¼ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
±¹°¡º°·Î´Â Áß³²¹ÌÀÇ Æó¾Ï ½ºÅ©¸®´× ½ÃÀåÀº ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª, ±âŸ ³²¹Ì·Î ±¸ºÐµË´Ï´Ù. 2022³â Áß³²¹ÌÀÇ Æó¾Ï ½ºÅ©¸®´× ½ÃÀåÀº ºê¶óÁúÀÌ Áö¹èÇß½À´Ï´Ù.
Siemens AG, Koninklijke Philips NV, Canon Inc, Medtronic, GE HealthCare technologies Inc´Â ³²¹Ì¡¤Á߾ӾƸ޸®Ä«ÀÇ Æó¾Ï ½ºÅ©¸®´× ½ÃÀå¿¡¼ »ç¾÷À» ¿î¿µÇÏ´Â ´ë±â¾÷ÀÔ´Ï´Ù.
The South & Central America lung cancer screening market is expected to grow from US$ 39.16 million in 2022 to US$ 68.95 million by 2030. It is estimated to grow at a CAGR of 7.3% from 2022 to 2030.
High cost of lung cancer screening tests fuel South & Central America lung cancer screening market.
Amid growing healthcare awareness in the region, lung cancer screening providers in the region has ample opportunities. These include collaborating with regional hospitals and clinics through which they can offer accessible lung cancer screening and leveraging telemedicine for remote areas. This approach not only detects lung cancer early but also improves patient outcomes, filling a crucial gap in the region's healthcare. By aligning with the rising demand for preventive care, these providers can establish a foothold in a promising market, ultimately contributing to enhanced public health and well-being across the region.
South & Central America Lung Cancer Screening Market Overview
The South & Central America lung cancer screening market is segmented into the Brazil, Argentina, and the Rest of South & Central America. The regional growth is attributed to various factors, such as the increasing incidence of lung cancer and growing awareness of lung cancer screening among people. Also, rising government support for screening has led to the further growth of the market.
The lung cancer screening market is being influenced by factors such as the increasing prevalence of cancer. For instance, as per Globocan 2020 report, lung cancer is Brazil's second most prevalent cancer. There were 88492 new cases of lung cancer found in Brazil.
Lung cancer screening is believed to be the standard of care worldwide. In Brazil, complications in its implementation related to the organization of the health system, access to CT scans and treatment methods, and cultural acceptance of the method restrict the process. There are challenges and barriers in carrying out the screening according to the local organization; however, it was possible to obtain satisfactory results in all scenarios.
According to Lung Cancer Policy Network, In Brazil, a coordinated approach to lung cancer screening is necessary, as health assistance is fragmented across the country and has resulted in significant health inequalities. The advantages of LDCT screening were recently described in the Second Brazilian Early Lung Cancer Screening Trial (BRELT2). Nevertheless, there are still many barriers to overcome before an organized screening program can be implemented nationwide, including inequitable access to screening equipment between public and private healthcare. To manage this challenge, as part of the Propulmao Mobile Project, the municipal health office in Barretos (Sao Paulo) collaborated with the local cancer hospital to deliver mobile LDCT screening and a smoking cessation intervention in the community.
South & Central America Lung Cancer Screening Market Revenue and Forecast to 2030 (US$ Million)
South & Central America Lung Cancer Screening Market Segmentation
The South & Central America lung cancer screening market is segmented into cancer type, technology, age group, end user, and country.
Based on cancer type, the South & Central America lung cancer screening market is segmented into non-small cell lung cancer (NSCLC), and small cell lung cancer. The non-small cell lung cancer (NSCLC) segment held a larger share of the South & Central America lung cancer screening market in 2022.
Based on technology, the South & Central America lung cancer screening market is segmented into chest X-ray, low dose computed tomography (LDCT), liquid biopsy, and others. Chest X-ray segment held the largest share of the South & Central America lung cancer screening market in 2022.
Based on age group, the South & Central America lung cancer screening market is segmented into 50 and older, and below 50. 50 and older segment held the larger share of the South & Central America lung cancer screening market in 2022.
Based on end user, the South & Central America lung cancer screening market is segmented into hospital, diagnostic centre, and others. Hospital segment held the largest share of the South & Central America lung cancer screening market in 2022.
Based on country, the South & Central America lung cancer screening market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America lung cancer screening market in 2022.
Siemens AG, Koninklijke Philips NV, Canon Inc, Medtronic, and GE HealthCare technologies Inc are some of the leading companies operating in the South & Central America lung cancer screening market.